PF 6671008

Drug Profile

PF 6671008

Alternative Names: PF-06671008; PF-6671008

Latest Information Update: 19 May 2016

Price : $50

At a glance

  • Originator MacroGenics
  • Developer Pfizer
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 10 May 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in USA (parenteral)
  • 04 Feb 2016 Pfizer plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease) in USA (NCT02659631)
  • 15 Jan 2016 Preclinical trials in Solid tumours (Late-stage disease, Metastatic disease) in USA (NCT02659631)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top